Perrigo names CEO and board chair
Perrigo announced today that it has appointed a new CEO and a new chairman to replace Joseph Papa, following Papa’s “resignation and departure.”
The Dublin-based drug maker, which has its North American headquarters in Allegan, said John Hendrickson has been named CEO, and Laurie Brlas has been named chairman of the board of directors. Both appointments are effective immediately.
Hendrickson has been with Perrigo for 27 years, serving most recently as president.
In that role, which he took on in 2015, he was responsible for 70 percent of the company’s employee base.
He was formerly EVP of Global Operations & Supply Chain between 2006 and 2015 and has held numerous management and operational leadership roles at Perrigo since he joined the company in 1989, including leading the U.S. Consumer Healthcare business from 2003 to 2006.
Hendrickson holds a bachelor’s degree in chemical engineering from the University of Michigan, a bachelor’s degree in chemistry from Hope College and an M.B.A. from the University of Notre Dame,
Hendrickson said he feels “privileged” to have been chosen as the company’s new CEO.
“Perrigo's long-tenured and cohesive leadership team has successfully positioned the company for a great future,” Hendrickson said. “As we implement our strategic plans across the organization, we are aware that we need to execute against our goals with a renewed sense of focus and operational discipline.
“I am excited to work with our board and our more than 13,000 employees worldwide to achieve near- and long-term goals and provide 'Quality Affordable Healthcare Products' to our customers and patients across the globe, while delivering shareholder value."
Brlas said Hendrickson is “an exceptional leader who is passionate about our mission, committed to our core values and with his breadth of experience, is uniquely qualified to successfully lead Perrigo into the future.”
“We are confident that he has the industry expertise and the operational track record to continue to drive growth,” Brlas said.
Papa will join multi-national specialty pharmaceutical company Valeant Pharmaceuticals International of Laval, Quebec as its chairman and CEO in early May.
Papa had been CEO of Perrigo since 2006 and was appointed as chairman of the board of directors in 2007.
Valeant said that during his tenure at Perrigo, Papa led “dramatic and consistent growth across the company,” building it into a global leader with net sales of more than $5 billion.